AIP
APGE icon

Ameritas Investment Partners’s Apogee Therapeutics APGE Stock Holding History

Ameritas Investment Partners’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$543K Buy
4,093
+427
+12% +$38.5K 0.01% 872
2026
Q1 		$309K Buy
3,666
+540
+17% +$39.2K 0.01% 1029
2025
Q4 		$236K Buy
3,126
+390
+14% +$24.6K 0.01% 1154
2025
Q3 		$109K Sell
2,736
-523
-16% -$20K ﹤0.01% 1640
2025
Q2 		$142K Sell
3,259
-580
-15% -$22.1K ﹤0.01% 1505
2025
Q1 		$143K Hold
3,839
– – ﹤0.01% 1464
2024
Q4 		$174K Hold
3,839
– – 0.01% 1410
2024
Q3 		$226K Buy
3,839
+296
+8% +$14.2K 0.01% 1231
2024
Q2 		$139K Sell
3,543
-583
-14% -$28.3K ﹤0.01% 1511
2024
Q1 		$274K Buy
4,126
+2,172
+111% +$94.8K 0.01% 1087
2023
Q4 		$54.6K Hold
1,954
– – ﹤0.01% 2123
2023
Q3 		$41.6K Buy
+1,954
New +$43K ﹤0.01% 2201

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Ameritas Investment Partners's APGE Position: Q2 2026 in Review

Ameritas Investment Partners increased its Apogee Therapeutics (APGE) stake by 12% in Q2 2026, buying an estimated $38.5K and bringing the position to 4,093 shares worth $543K. The position accounts for 0.01% of the portfolio, ranked #872.

Ameritas Investment Partners first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Ameritas Investment Partners held 4,093 shares of Apogee Therapeutics worth $543K as of Q2 2026.
  • Ameritas Investment Partners bought 427 Apogee Therapeutics shares in Q2 2026, an estimated $38.5K.
  • Apogee Therapeutics made up 0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #872 holding.
  • Ameritas Investment Partners first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.